Application 211175
- Type
- ANDA
- Sponsor
- FOUGERA PHARMS INC
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | TAZAROTENE | TAZAROTENE | CREAM;TOPICAL | 0.1% | No | No |
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A211175-001 | TAZAROTENE | TAZAROTENE | 0.1% | CREAM / TOPICAL | 2019-01-28 |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-01 22:54:32 | 2026-06 | A211175-001 | TAZAROTENE | 0.1% | CREAM / TOPICAL | 2019-01-28 | a50c72e98297… |
openFDA label cross-check#
Cross-check layer: openFDA label JSON enriches search and identifies hydration gaps. The DailyMed Structured Product Label remains the canonical label presentation on FDA.report. Every label matching the complete exact-identifier union is deduplicated and paginated below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Trilitas | TAZAROTENE | Perfero Pharma, Inc. | 1cf1faef-73b8-4ab2-a4c8-521f0bd3fc10 | 2026-05-18 | Warnings, Adverse reactions | TAZAROTENE |
| FABIOR | TAZAROTENE | Mayne Pharma | ae0afed7-1d60-45fd-a08b-8db094618521 | 2026-03-03 | Warnings, Adverse reactions | TAZAROTENE |
| Tazarotene | TAZAROTENE | Sun Pharmaceutical Industries, Inc. | 478ff059-9d7b-438e-a64e-c853dfac2872 | 2025-12-19 | Warnings, Adverse reactions | Tazarotene TAZAROTENE |
| Tazorac | TAZAROTENE | Almirall, LLC | 4e4e4b81-420e-4492-8a74-80b692a80057 | 2025-11-13 | Warnings, Adverse reactions | TAZAROTENE |
| TAZORAC | TAZAROTENE | Almirall, LLC | 021744d1-a6d7-4ad6-99c2-7187c24e64c6 | 2025-11-13 | Warnings, Adverse reactions | TAZAROTENE |
| Tazarotene | TAZAROTENE | Sun Pharmaceutical Industries, Inc. | 34d79c31-1568-4797-a4f5-31200c7788db | 2025-07-07 | Warnings, Adverse reactions | Tazarotene TAZAROTENE |
| Tazarotene | TAZAROTENE | Cosette Pharmaceuticals, Inc. | fa5caf83-29d5-8229-b125-d7736928f132 | 2025-03-10 | Warnings, Adverse reactions | Tazarotene TAZAROTENE |
| Tazarotene | TAZAROTENE | Solaris Pharma Corporation | f1c98c4a-f101-4f3c-851a-39c827415c46 | 2025-01-02 | Warnings, Adverse reactions | Tazarotene TAZAROTENE |
| TAZAROTENE | TAZAROTENE | Bryant Ranch Prepack | 91264c0a-223c-47b7-b537-071944f25790 | 2024-11-11 | Warnings, Adverse reactions | TAZAROTENE TAZAROTENE |
| tazarotene | TAZAROTENE | Mayne Pharma Inc. | 0e337598-f589-483f-a2ae-be7c319d7454 | 2024-06-04 | Warnings, Adverse reactions | tazarotene TAZAROTENE |
| TAZAROTENE | TAZAROTENE | Padagis Israel Pharmaceuticals Ltd | df5d65de-0693-4fd2-b335-f04ab1e201e7 | 2024-05-31 | Warnings, Adverse reactions | TAZAROTENE TAZAROTENE |
| TAZAROTENE | TAZAROTENE | Bryant Ranch Prepack | aa6fff2f-01c7-4669-be67-07cec82c768a | 2024-05-29 | Warnings, Adverse reactions | TAZAROTENE TAZAROTENE |
| Tazarotene | TAZAROTENE | Mayne Pharma | 0296f0e9-f940-45d9-987e-1ee26a7ca961 | 2024-03-05 | Warnings, Adverse reactions | Tazarotene TAZAROTENE |
| TAZAROTENE | TAZAROTENE | Padagis Israel Pharmaceuticals Ltd | ffd11dee-4266-4201-9573-1e82c2d30a63 | 2024-01-01 | Warnings, Adverse reactions | TAZAROTENE TAZAROTENE |
| TAZAROTENE | TAZAROTENE | Cosette Pharmaceuticals, Inc. | ecd718fd-c06e-4b3a-8aca-fa51e7c51a66 | 2023-11-29 | Warnings, Adverse reactions | TAZAROTENE TAZAROTENE |
| TAZAROTENE | TAZAROTENE | Cosette Pharmaceuticals, Inc. | 94749b8e-0d00-4257-a660-6d0fc8815fcf | 2023-11-29 | Warnings, Adverse reactions | TAZAROTENE TAZAROTENE |
| Arazlo | TAZAROTENE | Bausch Health US, LLC | d941ff25-c221-4a55-8012-0dcf3bbcbbd1 | 2023-09-26 | Warnings, Adverse reactions | TAZAROTENE |
NDC Listings For This Application#
| NDC | Name | Nonproprietary name | Labeler | Marketing category | Status |
|---|---|---|---|---|---|
| 0168-0454 | TAZAROTENE | tazarotene | Fougera Pharmaceuticals Inc. | ANDA | Current |
| 0168-0454 | TAZAROTENE | tazarotene | Fougera Pharmaceuticals Inc. | ANDA | Current |
| 0168-0455 | Tazarotene Cream | tazarotene | E. Fougera & Co. a division of Fougera Pharmaceuticals Inc. | ANDA | Current |
| 0168-0455 | Tazarotene Cream | tazarotene | E. Fougera & Co. a division of Fougera Pharmaceuticals Inc. | ANDA | Current |